SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 17, 2002; DOI 10.1182/blood-2001-12-0241. This Article Full Text (PDF) All Versions of this Article: 2001-12-0241v1 100/2/618    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dastugue, N. Articles by Berger, R. Search for Related Content PubMed PubMed Citation Articles by Dastugue, N. Articles by Berger, R. Related Collections Related Letter in Blood Online Social Bookmarking                   What's this? Submitted December 13, 2001 Accepted March 11, 2002 Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7) : a study of the Groupe Francais de Cytogenetique Hematologique (GFCH) Nicole Dastugue*, Marina Lafage-Pochitaloff, Marie-Pierre Pagès, Isabelle Radford, Christian Bastard, Pascaline Talmant, Marie Joelle Mozziconacci, Claude Léonard, Christelle Bilhou-Nabéra, Christine Cabrol, Anne-Marie Capodano, Pascale Cornillet-Lefebvre, Michel Lessard, Francine Mugneret, Christine Pérot, Sylvie Taviaux, Odile Fenneteaux, Eliane Duchayne, and Roland Berger * Corresponding author; email: dastugue.n{at}chu-toulouse.fr. In order to draw the cytogenetic profile of childhood and adult acute megakaryoblastic leukemia (M7), the Groupe Francais de Cytogenetique Hematologique collected 53 cases of M7 (30 children and 23 adults). Compared to other acute myeloid leukemias, M7 is characterized by a higher incidence of abnormalities, a higher complexity of karyotypes and a different distribution of abnormalities among children and adults. Nine cytogenetic groups were identified: normal karyotypes (group 1), patients with Down syndrome (group 2), numerical abnormalities only (group 3), t(1;22)(p13;q13) or OTT-MAL transcript (group 4), t(9;22)(q34;q11) (group 5), 3q21q26 (group 6), -5/del(5q) and/or -7/del(7q) (group 7), i(12)(p10) (group 8) and other structural changes (group 9). Groups 1, 2, 3 and 4 were exclusively composed of children (except one adult in group 3) whereas groups 5, 6, 7 and 8 were mainly made up of adults. The main clinical and hematological features of these groups were described. No new recurrent abnormality was identified but mapping of all breakpoints allowed us to specify several possible hot spots of rearrangement: 17q22-23, 11q14-21, 21q21-22 and 16q21-22-23. Although 90.5% of cases had no documented antecedent hematologic disorder or exposure to chemo-/radiotherapy, the morphological and the cytogenetic findings indicated that M7 might be a secondary leukemia more often than suggested by preceding history, particularly among adults. The concurrent analyses of morphological and cytogenetic data also led us to assume that the initial precursor involved might be more immature in adult than in childhood M7. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Chromosome 19 abnormalities are commonly seen in AML, M7 Stephen D. Nimer, Donal MacGrogan, Suresh Jhanwar, Sara Alvarez, Nicole Dastugue, and Roland Berger Blood 2002 100: 3838. [Full Text] [PDF] This article has been cited by other articles: S. Salek-Ardakani, G. Smooha, J. de Boer, N. J. Sebire, M. Morrow, L. Rainis, S. Lee, O. Williams, S. Izraeli, and H. J.M. Brady ERG Is a Megakaryocytic Oncogene Cancer Res., June 1, 2009; 69(11): 4665 - 4673. [Abstract] [Full Text] [PDF] S. Malinge, S. Izraeli, and J. D. Crispino Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome Blood, March 19, 2009; 113(12): 2619 - 2628. [Abstract] [Full Text] [PDF] S. Malinge, C. Ragu, V. Della-Valle, D. Pisani, S. N. Constantinescu, C. Perez, J.-L. Villeval, D. Reinhardt, J. Landman-Parker, L. Michaux, et al. Activating mutations in human acute megakaryoblastic leukemia Blood, November 15, 2008; 112(10): 4220 - 4226. [Abstract] [Full Text] [PDF] E. Forestier, S. Izraeli, B. Beverloo, O. Haas, A. Pession, K. Michalova, B. Stark, C. J. Harrison, A. Teigler-Schlegel, and B. Johansson Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study Blood, February 1, 2008; 111(3): 1575 - 1583. [Abstract] [Full Text] [PDF] T.-l. Gu, T. Mercher, J. W. Tyner, V. L. Goss, D. K. Walters, M. G. Cornejo, C. Reeves, L. Popova, K. Lee, M. C. Heinrich, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia Blood, July 1, 2007; 110(1): 323 - 333. [Abstract] [Full Text] [PDF] T. Mercher, G. Wernig, S. A. Moore, R. L. Levine, T.-L. Gu, S. Frohling, D. Cullen, R. D. Polakiewicz, O. A. Bernard, T. J. Boggon, et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model Blood, October 15, 2006; 108(8): 2770 - 2779. [Abstract] [Full Text] [PDF] G.C. T. Pipes, E. E. Creemers, and E. N. Olson The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes & Dev., June 15, 2006; 20(12): 1545 - 1556. [Abstract] [Full Text] [PDF] J.-P. Bourquin, A. Subramanian, C. Langebrake, D. Reinhardt, O. Bernard, P. Ballerini, A. Baruchel, H. Cave, N. Dastugue, H. Hasle, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling PNAS, February 28, 2006; 103(9): 3339 - 3344. [Abstract] [Full Text] [PDF] E. Jourdan, J.-M. Boiron, N. Dastugue, N. Vey, G. Marit, F. Rigal-Huguet, L. Molina, N. Fegueux, A. Pigneux, C. Recher, et al. Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience J. Clin. Oncol., October 20, 2005; 23(30): 7676 - 7684. [Abstract] [Full Text] [PDF] L. Rainis, T. Toki, J. E. Pimanda, E. Rosenthal, K. Machol, S. Strehl, B. Gottgens, E. Ito, and S. Izraeli The Proto-Oncogene ERG in Megakaryoblastic Leukemias Cancer Res., September 1, 2005; 65(17): 7596 - 7602. [Abstract] [Full Text] [PDF] L. Garderet, M. Labopin, N.-C. Gorin, E. Polge, A. Baruchel, G. Meloni, J. Ortega, J. Vossen, D. Bunjes, G. Leverger, et al. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) Blood, January 1, 2005; 105(1): 405 - 409. [Abstract] [Full Text] [PDF] M. Ahmed, A. Sternberg, G. Hall, A. Thomas, O. Smith, A. O'Marcaigh, R. Wynn, R. Stevens, M. Addison, D. King, et al. Natural history of GATA1 mutations in Down syndrome Blood, April 1, 2004; 103(7): 2480 - 2489. [Abstract] [Full Text] [PDF] S. Gurbuxani, P. Vyas, and J. D. Crispino Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome Blood, January 15, 2004; 103(2): 399 - 406. [Abstract] [Full Text] [PDF] L. Rainis, D. Bercovich, S. Strehl, A. Teigler-Schlegel, B. Stark, J. Trka, N. Amariglio, A. Biondi, I. Muler, G. Rechavi, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21 Blood, August 1, 2003; 102(3): 981 - 986. [Abstract] [Full Text] [PDF] J. K. Hitzler, J. Cheung, Y. Li, S. W. Scherer, and A. Zipursky GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome Blood, June 1, 2003; 101(11): 4301 - 4304. [Abstract] [Full Text] [PDF] S. D. Nimer, D. MacGrogan, S. Jhanwar, S. Alvarez, N. Dastugue, and R. Berger Chromosome 19 abnormalities are commonly seen in AML, M7 Blood, November 15, 2002; 100(10): 3838 - 3838. [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020